Pharmacogenetic testing by polymorphic markers G1846A (CYP2D6*4) and C100T (CYP2D6*10) of the CYP2D6 gene in coronary heart disease patients taking ββ-blockers in the Republic of Sakha (YAKUTIA)
Journal Name: Drug Metabolism and Personalized Therapy Issue: Ahead of print
Source: Drug Metabolism and Personalized Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Coronary Heart Disease | Drugs & Pharmacology | Genetics | Heart | Heart Disease